Ephrin (Eph) receptor A1, A4, A5 and A7 expression in human non-small cell lung carcinoma: Associations with clinicopathological parameters, tumor proliferative capacity and patients' survival

BMC Clinical Pathology

Volumn 14, Issue 1, 2014, Pages

  Giaginis, Constantinos ^a,b   Tsoukalas, Nikolaos ^c   Bournakis, Evangelos ^c   Alexandrou, Paraskevi ^a   Kavantzas, Nikolaos ^a   Patsouris, Efstratios ^a   Theocharis, Stamatios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF THE AEGEAN   (Greece)

^c 401 GENERAL MILITARY HOSPITAL OF ATHENS   (Greece)

Author keywords

Clinicopathological parameters; Ephrin receptors; Immunohistochemistry; Non small cell lung carcinoma; Prognosis

Indexed keywords

EPHRIN RECEPTOR A1; EPHRIN RECEPTOR A4; EPHRIN RECEPTOR A5; EPHRIN RECEPTOR A7;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISTANT METASTASIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; TISSUE MICROARRAY;

EID: 84893204229     PISSN: None     EISSN: 14726890     Source Type: Journal    
DOI: 10.1186/1472-6890-14-8     Document Type: Article

References (42)

1. Role of the ephrin and Ephrin receptor tyrosine kinase families in angiogenesis and development of the cardiovascular system. Zhang J, Hughes SE, J Pathol 2006 208 453 461 10.1002/path.1937 16470907 (Pubitemid 43329333)
2. Eph-ephrin bidirectional signaling in physiology and disease. Pasquale EB, Cell 2008 133 38 52 10.1016/j.cell.2008.03.011 18394988 (Pubitemid 351442996)
3. Diverse role for the Eph family of receptor tyrosine kinases in carcinogenesis. Nakamoto M, Bergemann AD, Microscopy Res Technique 2002 59 58 67 10.1002/jemt.10177
4. The role of ephrins and Eph receptors in cancer. Surawska H, Ma PC, Salgia R, Cytokine Growth Factor Rev 2004 15 419 433 10.1016/j.cytogfr.2004.09. 002 15561600 (Pubitemid 39550453)
5. Eph receptor signalling; dimerisation just isn't enough. Vearing CJ, Lackmann M, Growth Factors 2005 23 67 76 10.1080/08977190500055869 16019428 (Pubitemid 41656872)
6. The ephrins and Eph receptors in angiogenesis. Cheng N, Brantley DM, Chen J, Cytokine Growth Factor Rev 2002 13 75 85 10.1016/S1359-6101(01)00031-4 11750881 (Pubitemid 34436963)
7. Eph receptor tyrosine kinase in angiogenesis: From development to disease. Brandley-Sieders DM, Chen J, Angiogenesis 2007 7 17 28
8. EPH receptors in cancer. Castaño J, Davalos V, Schwartz S Jr, et al. Histol Histopathol 2008 23 1011 1023 18498077
9. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Pasquale EB, Nat Rev Cancer 2010 10 165 180 10.1038/nrc2806 20179713
10. Eph-dependent cell-cell adhesion and segregation in development and cancer. Nievergall E, Lackmann M, Janes PW, Cell Mol Life Sci 2012 69 1813 1842 10.1007/s00018-011-0900-6 22204021
11. Eph receptors and ephrins as targets for cancer therapy. Xi HQ, Wu XS, Wei B, Chen L, J Cell Mol Med 2012 16 2894 2909 10.1111/j.1582-4934.2012.01612.x 22862837
12. Cancer statistics, 2012. Siegel R, Naishadham D, Jemal A, CA Cancer J Clin 2012 62 10 29 10.3322/caac.20138 22237781
13. Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. D' Addario G, Felip E, Ann Oncol 2009 20 68 70 19454467
14. Epidemiology of lung cancer: looking to the future. Alberg AJ, Brock MV, Samet JM, J Clin Oncol 2005 23 3175 3185 10.1200/JCO.2005.10.462 15886304 (Pubitemid 46217457)
15. The impact of declining smoking on radon-related lung cancer in the United States. Méndez D, Alshanqeety O, Warner KE, Lantz PM, Courant PN, Am J Public Health 2011 101 310 314 10.2105/AJPH.2009.189225 21228294
16. Eph/ephrin profiling in human breast cancer reveals significant associations between expression level and clinical outcome. Brantley-Sieders DM, Jiang A, Sarma K, et al. PLoS One 2011 6 24426 10.1371/journal.pone.0024426 21935409
17. Clinical relevance of Ephs and ephrins in cancer: lessons from breast, colorectal, and lung cancer profiling. Brantley-Sieders DM, Semin Cell Dev Biol 2012 23 102 108 10.1016/j.semcdb.2011.10.014 22040912
18. Clinical significance of Ephrin (Eph)-A1, -A2, -A4, -A5 and -A7 receptors in pancreatic ductal adenocarcinoma. Giaginis C, Tsourouflis G, Zizi-Serbetzoglou A, et al. Pathol Oncol Res 2010 16 267 276 10.1007/s12253-009-9221-6 19949912
19. Eph-A2 and Eph-A4 expression in human benign and malignant thyroid lesions: an immunohistochemical study. Karidis NP, Giaginis C, Tsourouflis G, et al. Med Sci Monit 2011 17 R257 BR265 21873938
20. Greene FLPD, Fleming ID, Fritz AG, Balch CM, Haller DG, Morrow M, AJCC cancer staging manual New York: Springer-Verlag 6 2002
21. Revisions to the TNM Staging of Non-Small Cell Lung Cancer: Rationale, Clinicoradiologic Implications, and Persistent Limitations. Nair A, Klusmann MJ, Jogeesvaran KH, et al. Radiographics 2011 31 215 238 10.1148/rg.311105039 21257943
22. Seventh edition of the cancer staging manual and stage grouping of lung cancer: quick reference chart and diagrams. Lababede O, Meziane M, Rice T, Chest 2011 139 183 189 10.1378/chest.10-1099 21208878
23. Expression of peroxisome proliferator activated receptor-gamma (PPAR-γ) in human non-small cell lung carcinoma: correlation with clinicopathological parameters, proliferation and apoptosis related molecules and patients' survival. Giaginis C, Politi E, Alexandrou P, et al. Pathol Oncol Res 2012 18 875 883 10.1007/s12253-012-9517-9 22426809
24. Downregulation of EphA1 in colorectal carcinomas correlates with invasion and metastasis. Dong Y, Wang J, Sheng Z, et al. Mod Pathol 2009 22 151 160 10.1038/modpathol.2008.188 19011600
25. Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder. Abraham S, Knapp DW, Cheng L, et al. Clin Cancer Res 2006 12 353 360 10.1158/1078-0432.CCR-05-1505 16428472 (Pubitemid 43166121)
26. Expression of EphA2 and EphrinA-1 in vulvar carcinomas and its relation to prognosis. Holm R, Knopp S, Suo Z, et al. J Clin Pathol 2007 60 1086 1091 10.1136/jcp.2006.041194 17158642 (Pubitemid 47612638)
27. Expression profile of Eph receptors and ephrin ligands in human skin and downregulation of EphA1 in nonmelanoma skin cancer. Hafner C, Becker B, Landthaler M, Vogt T, Mod Pathol 2006 19 1369 1377 10.1038/modpathol.3800660 16862074 (Pubitemid 44423085)
28. The roles and therapeutic potentials of Ephs and ephrins in lung cancer. Li JJ, Xie D, Exp Cell Res 2013 319 152 159 10.1016/j.yexcr.2012.08.005 22960108
29. Expression of the receptor tyrosine kinase EphA2 is increased in smokers and predicts poor survival in non-small cell lung cancer. Brannan JM, Dong W, Prudkin L, et al. Clin Cancer Res 2009 15 4423 4430 10.1158/1078-0432.CCR-09- 0473 19531623
30. Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. Kinch MS, Moore MB, Harpole DH Jr, Clin Cancer Res 2003 9 613 618 12576426 (Pubitemid 36182592)
31. Higher expression of EphA2 and ephrin-A1 is related to favorable clinicopathological features in pathological stage I non-small cell lung carcinoma. Ishikawa M, Miyahara R, Sonobe M, et al. Lung Cancer 2012 76 431 438 10.1016/j.lungcan.2011.12.004 22236865
32. Global Evaluation of Eph receptors and ephrins in lung adenocarcinomas identifies EphA4 as an inhibitor of cell migration and invasion. Saintigny P, Peng S, Zhang L, et al. Mol Cancer Ther 2012 11 2021 2032 10.1158/1535-7163.MCT- 12-0030 22807579
33. The EPHB6 receptor tyrosine kinase is a metastasis suppressor that is frequently silenced by promoter DNA hypermethylation in non-small cell lung cancer. Yu J, Bulk E, Ji P, et al. Clin Cancer Res 2010 16 2275 2283 10.1158/1078-0432.CCR-09-2000 20371680
34. Somatic mutations affect key pathways in lung adenocarcinoma. Ding L, Getz G, Wheeler DA, et al. Nature 2008 455 1069 1075 10.1038/nature07423 18948947
35. EphB4 gene polymorphism and protein expression in non-small-cell lung cancer. Zheng MF, Ji Y, Wu XB, et al. Mol Med Report 2012 6 405 408
36. Emerging strategies for EphA2 receptor targeting for cancer therapeutics. Tandon M, Vemula SV, Mittal SK, Expert Opin Ther Targets 2011 15 31 51 10.1517/14728222.2011.538682 21142802
37. The Eph/Ephrin family in cancer metastasis: communication at the service of invasion. Kandouz M, Cancer Metastasis Rev 2012 31 353 373 10.1007/s10555-012-9352-1 22549394
38. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Landen CN Jr, Chavez-Reyes A, Bucana C, et al. Cancer Res 2005 65 6910 6918 10.1158/0008-5472.CAN-05-0530 16061675 (Pubitemid 41060730)
39. Dual targeting of EphA2 and FAK in ovarian carcinoma. Shahzad MM, Lu C, Lee JW, et al. Cancer Biol Ther 2009 8 1027 1034 10.4161/cbt.8.11.8523 19395869
40. Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. Zhuang G, Brantley-Sieders DM, Vaught D, et al. Cancer Res 2010 70 299 308 10.1158/0008-5472.CAN-09-1845 20028874
41. Activation of the EGFR gene target EphA2 inhibits epidermal growth factor-induced cancer cell motility. Larsen AB, Pedersen MW, Stockhausen MT, et al. Mol Cancer Res 2007 5 283 293 10.1158/1541-7786.MCR-06-0321 17374733 (Pubitemid 46569779)
42. Secreted form of EphA7 in lung cancer. Tsuboi M, Mori H, Bunai T, et al. Int J Cancer 2010 36 635 640